Family with sequence similarity 3 gene family and nonalcoholic fatty liver disease

Journal of Gastroenterology and Hepatology (Australia)

Volumn 28, Issue SUPPL 1, 2013, Pages 105-111

  Yang, Jichun ^a,b   Guan, Youfei ^a,b  

^a PEKING UNIVERSITY   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

FAM3 gene family; NAFLD; PANDER; Steatosis

Indexed keywords

CYTOKINE; FAMILY WITH SEQUENCE SIMILARITY 3 PROTEIN; FAMILY WITH SEQUENCE SIMILARITY 3A PROTEIN; FAMILY WITH SEQUENCE SIMILARITY 3B PROTEIN; FAMILY WITH SEQUENCE SIMILARITY 3C PROTEIN; FAMILY WITH SEQUENCE SIMILARITY 3D PROTEIN; FAS ANTIGEN; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; STEROL REGULATORY ELEMENT BINDING PROTEIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TRANSCRIPTION FACTOR FKHR; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ENERGY METABOLISM; GENE SEQUENCE; GLUCOSE METABOLISM; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; LIPID STORAGE; LIPOGENESIS; MULTIGENE FAMILY; NONALCOHOLIC FATTY LIVER; NONHUMAN; PANCREAS ISLET BETA CELL; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SECRETION; REVIEW;

EID: 84880402879     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12033     Document Type: Review

References (73)

1. Qureshi K, Abrams GA. Metabolic liver disease of obesity and role of adipose tissue in the pathogenesis of nonalcoholic fatty liver disease. World J. Gastroenterol. 2007; 13: 3540-3553.
2. Brunt EM. Pathology of nonalcoholic fatty liver disease. Nat. Rev. 2010; 7: 195-203.
3. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology (Baltimore, Md.) 2010; 51: 1820-1832.
4. Yang Z, Wang X, Wen J etal. Prevalence of non-alcoholic fatty liver disease and its relation to hypoadiponectinaemia in the middle-aged and elderly Chinese population. Arch. Med. Sci. 2011; 7: 665-672.
5. Fan JG, Farrell GC. Epidemiology of non-alcoholic fatty liver disease in China. J. Hepatol. 2009; 50: 204-210.
6. Musso G, Gambino R, Cassader M. Emerging molecular targets for the treatment of nonalcoholic fatty liver disease. Annu. Rev. Med. 2010; 61: 375-392.
7. Bechmann LP, Hannivoort RA, Gerken G, Hotamisligil GS, Trauner M, Canbay A. The interaction of hepatic lipid and glucose metabolism in liver diseases. J. Hepatol. 2012; 56: 952-964.
8. Bugianesi E, Moscatiello S, Ciaravella MF, Marchesini G. Insulin resistance in nonalcoholic fatty liver disease. Curr. Pharm. Des. 2010; 16: 1941-1951.
9. Chakrabarti P, Kandror KV. Adipose triglyceride lipase: a new target in the regulation of lipolysis by insulin. Curr. Diabetes Rev. 2011; 7: 270-277.
10. Lettner A, Roden M. Ectopic fat and insulin resistance. Curr. Diab. Rep. 2008; 8: 185-191.
11. Carter-Kent C, Zein NN, Feldstein AE. Cytokines in the pathogenesis of fatty liver and disease progression to steatohepatitis: implications for treatment. Am. J. Gastroenterol. 2008; 103: 1036-1042.
12. Wieckowska A, Papouchado BG, Li Z, Lopez R, Zein NN, Feldstein AE. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am. J. Gastroenterol. 2008; 103: 1372-1379.
13. Nakayama H, Otabe S, Yuan X etal. Effects of adiponectin transgenic expression in liver of nonalcoholic steatohepatitis model mice. Metabolism 2009; 58: 901-908.
14. Otabe S, Yuan X, Fukutani T etal. Overexpression of human adiponectin in transgenic mice results in suppression of fat accumulation and prevention of premature death by high-calorie diet. Am. J. Physiol. 2007; 293: E210-218.
15. Zhou M, Xu A, Tam PK etal. Mitochondrial dysfunction contributes to the increased vulnerabilities of adiponectin knockout mice to liver injury. Hepatology 2008; 48: 1087-1096.
16. Szalowska E, Elferink MG, Hoek A, Groothuis GM, Vonk RJ. Resistin is more abundant in liver than adipose tissue and is not upregulated by lipopolysaccharide. J. Clin. Endocrinol. Metab. 2009; 94: 3051-3057.
17. Zhu Y, Xu G, Patel A etal. Cloning, expression, and initial characterization of a novel cytokine-like gene family. Genomics 2002; 80: 144-150.
18. Cao X, Gao Z, Robert CE etal. Pancreatic-derived factor (FAM3B), a novel islet cytokine, induces apoptosis of insulin-secreting beta-cells. Diabetes 2003; 52: 2296-2303.
19. Burkhardt BR, Greene SR, White P etal. PANDER-induced cell-death genetic networks in islets reveal central role for caspase-3 and cyclin-dependent kinase inhibitor 1A (p21). Gene 2006; 369: 134-141.
20. Burkhardt BR, Yang MC, Robert CE etal. Tissue-specific and glucose-responsive expression of the pancreatic derived factor (PANDER) promoter. Biochim. Biophys. Acta 2005; 1730: 215-225.
21. Cao X, Yang J, Burkhardt BR etal. Effects of overexpression of pancreatic derived factor (FAM3B) in isolated mouse islets and insulin-secreting betaTC3 cells. Am. J. Physiol. Endocrinol. Metab. 2005; 289: E543-550.
22. Li J, Chi Y, Wang C etal. Pancreatic-derived factor promotes lipogenesis in the mouse liver: role of the Forkhead box 1 signaling pathway. Hepatology 2011; 53: 1906-1916.
23. Robert-Cooperman CE, Carnegie JR, Wilson CG etal. Targeted disruption of pancreatic-derived factor (PANDER, FAM3B) impairs pancreatic beta-cell function. Diabetes 2010; 59: 2209-2218.
24. Wang C, Burkhardt BR, Guan Y, Yang J. Role of pancreatic-derived factor in type 2 diabetes: evidence from pancreatic beta cells and liver. Nutr. Rev. 2012; 70: 100-106.
25. Yang J, Robert CE, Burkhardt BR etal. Mechanisms of glucose-induced secretion of pancreatic-derived factor (PANDER or FAM3B) in pancreatic beta-cells. Diabetes 2005; 54: 3217-3228.
26. Yang J, Wang C, Li J etal. PANDER binds to the liver cell membrane and inhibits insulin signaling in HepG2 cells. FEBS Lett. 2009; 583: 3009-3015.
27. de Wit NJ, Ijssennagger N, Oosterink E etal. Oit1/Fam3D, a gut-secreted protein displaying nutritional status-dependent regulation. J. Nutr. Biochem. 2012; 23: 1425-1433.
28. Robert-Cooperman CE, Wilson CG, Burkhardt BR. PANDER KO mice on high-fat diet are glucose intolerant yet resistant to fasting hyperglycemia and hyperinsulinemia. FEBS Lett. 2011; 585: 1345-1349.
29. Wilson CG, Robert-Cooperman CE, Burkhardt BR. PANcreatic-DERived factor: novel hormone PANDERing to glucose regulation. FEBS Lett. 2011; 585: 2137-2143.
30. Wilson CG, Schupp M, Burkhardt BR, Wu J, Young RA, Wolf BA. Liver-specific overexpression of pancreatic-derived factor (PANDER) induces fasting hyperglycemia in mice. Endocrinology 2010; 151: 5174-5184.
31. Ellingsgaard H, Hauselmann I, Schuler B etal. Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat. Med. 2011; 17: 1481-1489.
32. Donath MY, Boni-Schnetzler M, Ellingsgaard H, Halban PA, Ehses JA. Cytokine production by islets in health and diabetes: cellular origin, regulation and function. Trends Endocrinol. Metab. 2010; 21: 261-267.
33. Xu W, Gao Z, Wu J, Wolf BA. Interferon-gamma-induced regulation of the pancreatic derived cytokine FAM3B in islets and insulin-secreting betaTC3 cells. Mol. Cell. Endocrinol. 2005; 240: 74-81.
34. Burkhardt BR, Cook JR, Young RA, Wolf BA. PDX-1 interaction and regulation of the pancreatic derived factor (PANDER, FAM3B) promoter. Biochim. Biophys. Acta 2008; 1779: 645-651.
35. Wang O, Cai K, Pang S etal. Mechanisms of glucose-induced expression of pancreatic-derived factor in pancreatic beta-cells. Endocrinology 2008; 149: 672-680.
36. Hou X, Wang O, Li Z etal. Upregulation of pancreatic derived factor (FAM3B) expression in pancreatic beta-cells by MCP-1 (CCL2). Mol. Cell. Endocrinol. 2011; 343: 18-24.
37. Xiang JN, Chen DL, Yang LY. Effect of PANDER in betaTC6-cell lipoapoptosis and the protective role of exendin-4. Biochem. Biophys. Res. Commun. 2012; 421: 701-706.
38. Zhou Y, Wang C, Li J etal. Expression of PANDER in the pancreas of diabetic mice. Basic Clin. Med. 2012; 32: 756-760.
39. Shushan EB, Cerasi E, Melloul D. Regulation of the insulin gene by glucose: stimulation of trans-activation potency of human PDX-1 N-terminal domain. DNA Cell Biol. 1999; 18: 471-479.
40. Robert C, Wu J, Burkhardt BR, Wolf B. Transgenic mice overexpressing the novel islet specific cytokine, PANDER, exhibit glucose intolerance. Diabetes 2005; 54 (Suppl. 1): A400.
41. Carnegie JR, Robert-Cooperman CE, Wu J, Young RA, Wolf BA, Burkhardt BR. Characterization of the expression, localization, and secretion of PANDER in alpha-cells. Mol. Cell. Endocrinol. 2010; 325: 36-45.
42. Yang J, Gao Z, Robert CE etal. Structure-function studies of PANDER, an islet specific cytokine inducing cell death of insulin-secreting beta cells. Biochemistry 2005; 44: 11342-11352.
43. Zhuang F, Guan Q, Gao L etal. Levels of serum pancreatic derived factor (PANDER) and their correlations with islet β cell function in newly diagnosed type 2 diabetic patients. J. Shandong Univ. (Health Sci.) 2010; 48: 1-4.
44. Kahn SE, D'Alessio DA, Schwartz MW etal. Evidence of cosecretion of islet amyloid polypeptide and insulin by beta-cells. Diabetes 1990; 39: 634-638.
45. Zheng X, Ren W, Zhang S etal. Serum levels of proamylin and amylin in normal subjects and patients with impaired glucose regulation and type 2 diabetes mellitus. Acta Diabetol. 2010; 47: 265-270.
46. Schmitz O, Brock B, Rungby J. Amylin agonists: a novel approach in the treatment of diabetes. Diabetes 2004; 53 (Suppl. 3): S233-238.
47. Lutz TA. Control of energy homeostasis by amylin. Cell. Mol. Life Sci. 2012; 69: 1947-1965.
48. Younk LM, Mikeladze M, Davis SN. Pramlintide and the treatment of diabetes: a review of the data since its introduction. Expert Opin. Pharmacother. 2010; 12: 1439-1451.
49. Zhu T, Wang Y, He B, Zang J, He Q, Zhang W. Islet amyloid polypeptide acts on glucose-stimulated beta cells to reduce voltage-gated calcium channel activation, intracellular Ca(2+) concentration, and insulin secretion. Diabetes Metab. Res. Rev. 2011; 27: 28-34.
50. Li XL, Chen T, Wong YS etal. Involvement of mitochondrial dysfunction in human islet amyloid polypeptide-induced apoptosis in INS-1E pancreatic beta cells: an effect attenuated by phycocyanin. Int. J. Biochem. Cell Biol. 2011; 43: 525-534.
51. Janson J, Soeller WC, Roche PC etal. Spontaneous diabetes mellitus in transgenic mice expressing human islet amyloid polypeptide. Proc. Natl Acad. Sci. U. S. A. 1996; 93: 7283-7288.
52. Butler AE, Jang J, Gurlo T, Carty MD, Soeller WC, Butler PC. Diabetes due to a progressive defect in beta-cell mass in rats transgenic for human islet amyloid polypeptide (HIP Rat): a new model for type 2 diabetes. Diabetes 2004; 53: 1509-1516.
53. Gebre-Medhin S, Mulder H, Pekny M etal. Increased insulin secretion and glucose tolerance in mice lacking islet amyloid polypeptide (amylin). Biochem. Biophys. Res. Commun. 1998; 250: 271-277.
54. Ye JM, Lim-Fraser M, Cooney GJ etal. Evidence that amylin stimulates lipolysis in vivo: a possible mediator of induced insulin resistance. Am. J. Physiol. Endocrinol. Metab. 2001; 280: E562-569.
55. Bryer-Ash M, Follett L, Hodges N, Wimalawansa S. Amylin-mediated reduction in insulin sensitivity corresponds to reduced insulin receptor kinase activity in the rat in vivo. Metabolism 1995; 44: 705-711.
56. Hiji M, Takahashi T, Fukuba H, Yamashita H, Kohriyama T, Matsumoto M. White matter lesions in the brain with frontotemporal lobar degeneration with motor neuron disease: TDP-43-immunopositive inclusions co-localize with p62, but not ubiquitin. Acta Neuropathol. 2008; 116: 183-191.
57. Sparks JD, Dong HH. FoxO1 and hepatic lipid metabolism. Curr. Opin. Lipidol. 2009; 20: 217-226.
58. Kamagate A, Qu S, Perdomo G etal. FoxO1 mediates insulin-dependent regulation of hepatic VLDL production in mice. J. Clin. Invest. 2008; 118: 2347-2364.
59. Valenti L, Rametta R, Dongiovanni P etal. Increased expression and activity of the transcription factor FOXO1 in nonalcoholic steatohepatitis. Diabetes 2008; 57: 1355-1362.
60. Zatara G, Hertz R, Shaked M etal. Suppression of FoxO1 activity by long-chain fatty acyl analogs. Diabetes 2011; 60: 1872-1881.
61. Steinberg GR, Kemp BE. AMPK in health and disease. Physiol. Rev. 2009; 89: 1025-1078.
62. Moran-Salvador E, Lopez-Parra M, Garcia-Alonso V etal. Role for PPARgamma in obesity-induced hepatic steatosis as determined by hepatocyte- and macrophage-specific conditional knockouts. FASEB J. 2011; 25: 2538-2550.
63. Gavrilova O, Haluzik M, Matsusue K etal. Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J. Biol. Chem. 2003; 278: 34268-34276.
64. Matsusue K, Haluzik M, Lambert G etal. Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. J. Clin. Invest. 2003; 111: 737-747.
65. Zhou J, Febbraio M, Wada T etal. Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPARgamma in promoting steatosis. Gastroenterology 2008; 134: 556-567.
66. He J, Lee JH, Febbraio M, Xie W. The emerging roles of fatty acid translocase/CD36 and the aryl hydrocarbon receptor in fatty liver disease. Exp. Biol. Med. (Maywood) 2011; 236: 1116-1121.
67. Koonen DP, Jacobs RL, Febbraio M etal. Increased hepatic CD36 expression contributes to dyslipidemia associated with diet-induced obesity. Diabetes 2007; 56: 2863-2871.
68. Steinberg SJ, Wang SJ, McGuinness MC, Watkins PA. Human liver-specific very-long-chain acyl-coenzyme A synthetase: cDNA cloning and characterization of a second enzymatically active protein. Mol. Genet. Metab. 1999; 68: 32-42.
69. Krammer J, Digel M, Ehehalt F, Stremmel W, Fullekrug J, Ehehalt R. Overexpression of CD36 and acyl-CoA synthetases FATP2, FATP4 and ACSL1 increases fatty acid uptake in human hepatoma cells. Int. J. Med. Sci. 2011; 8: 599-614.
70. Solmi R, De Sanctis P, Zucchini C etal. Search for epithelial-specific mRNAs in peripheral blood of patients with colon cancer by RT-PCR. Int. J. Oncol. 2004; 25: 1049-1056.
71. Waerner T, Alacakaptan M, Tamir I etal. ILEI: a cytokine essential for EMT, tumor formation, and late events in metastasis in epithelial cells. Cancer Cell 2006; 10: 227-239.
72. Gronborg M, Kristiansen TZ, Iwahori A etal. Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach. Mol. Cell. Proteomics 2006; 5: 157-171.
73. Pilipenko VV, Reece A, Choo DI, Greinwald JH Jr. Genomic organization and expression analysis of the murine Fam3c gene. Gene 2004; 335: 159-168.